CoChat
Sign Up
Cited by 81

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Plasma PCSK9 levels correlate with cholesterol in men but not in women.

Mayne, Janice, Raymond, Angela, Chaplin, Anna, Cousins, Marion, Kaefer, Nadine, Gyamera-Acheampong, Charles, Seidah, Nabil G., Mbikay, Majambu, Chrétien, Michel, Ooi, Teik Chye·2007·Biochemical and Biophysical Research Communications
DOI 10.1016/j.bbrc.2007.07.029
Open this paper in CoChat — free account

Abstract

Proprotein convertase subtilisin kexin-like 9 (PCSK9) is a secreted glycoprotein that negatively regulates low density lipoprotein receptor (LDLR) levels. Several single nucleotide polymorphisms (SNPs) in PCSK9 have been linked to autosomal dominant hypercholesterolemia (ADH). Conversely, hypocholesterolemia associates with both 'loss of function' nonsense and missense SNPs in PCSK9. We examined the association of plasma PCSK9 with lipoprotein parameters in 182 normolipidemics. For men (n=98) plasma PCSK9 averaged 6.08+/-1.96 microg/ml and Spearman analysis revealed significant correlation between it and total cholesterol (TC), LDLC, and TC/high density lipoprotein (HDLC) (r=0.276, 0.282, and 0.228, respectively). For women (n=84) plasma PCSK9 averaged 6.46+/-1.99 microg/ml having no correlation with TC, LDLC or TC/HDLC. The ratio of plasma PCSK9/LDLC increased in men carrying 'loss of function' PCSK9 variations. Our results suggest a gender difference in PCSK9 regulation and function with PCSK9 correlated to TC and LDLC in men but not women.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.bbrc.2007.07.029

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 25

  1. Seidah, 2002, Precursor convertases in the secretory pathway, cytosol and extracellular milieu, Essays Biochem., 38, 79, 10.1042/bse0380079 · DOI
  2. Seidah, 2003, The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation, Proc. Natl. Acad. Sci. USA, 100, 928, 10.1073/pnas.0335507100 · DOI · Paper page
  3. Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat. Genet., 34, 154, 10.1038/ng1161 · DOI · Paper page
  4. Austin, 2004, Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review, Am. J. Epidemiol., 160, 407, 10.1093/aje/kwh236 · DOI · Paper page
  5. Timms, 2004, A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree, Hum. Genet., 114, 349, 10.1007/s00439-003-1071-9 · DOI
  6. Zhang, 2007, Binding of PCSK9 to EGF-A repeat of LDL receptor decreases receptor recycling and increases degradation, J. Biol. Chem., 282, 18602, 10.1074/jbc.M702027200 · DOI · Paper page
  7. Nassoury, 2007, The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR, Traffic, 6, 718, 10.1111/j.1600-0854.2007.00562.x · DOI · Paper page
  8. Benjannet, 2004, NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol, J. Biol. Chem., 279, 48865, 10.1074/jbc.M409699200 · DOI · Paper page
  9. Lagace, 2006, Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice, J. Clin. Invest., 116, 2995, 10.1172/JCI29383 · DOI · Paper page
  10. Rashid, 2005, Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9, Proc. Natl. Acad. Sci. USA, 102, 5374, 10.1073/pnas.0501652102 · DOI · Paper page
  11. Yue, 2006, The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population, Hum. Mutat., 27, 460, 10.1002/humu.20316 · DOI
  12. Miyake, 2007, Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population, Atherosclerosis
  13. Kotowski, 2006, A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol, Am. J. Hum. Genet., 78, 410, 10.1086/500615 · DOI · Paper page
  14. Fasano, 2007, A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol, Arterioscler. Thromb. Vasc. Biol., 27, 677, 10.1161/01.ATV.0000255311.26383.2f · DOI
  15. Berge, 2006, Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy, Arterioscler. Thromb. Vasc. Biol., 26, 1094, 10.1161/01.ATV.0000204337.81286.1c · DOI · Paper page
  16. Cameron, 2006, Effect of mutations in the PCSK9 gene on the cell surface LDL receptors, Hum. Mol. Genet., 15, 1551, 10.1093/hmg/ddl077 · DOI · Paper page
  17. Benjannet, 2006, The proprotein convertase (PC) PCSK9 is inactivated by Furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications, J. Biol. Chem., 281, 30561, 10.1074/jbc.M606495200 · DOI · Paper page
  18. Chowdhury, 2001, Generation of high titer antisera in rabbits by DNA immunization, J. Immunol. Methods, 249, 147, 10.1016/S0022-1759(00)00353-7 · DOI
  19. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. The Lipid Research Clinics Program Epidemiology Committee, Circulation 60 (1979) 427–439. · DOI
  20. Shioji, 2004, Genetic variants in PCSK9 affect the cholesterol level in Japanese, J. Hum. Genet., 49, 109, 10.1007/s10038-003-0114-3 · DOI
  21. Evans, 2006, The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women, BMC Med. Genet., 7, 66, 10.1186/1471-2350-7-66 · DOI
  22. Smith, 2004, The low-density lipoprotein receptor is regulated by estrogen and forms a functional complex with the estrogen-regulated protein ezrin in pituitary GH3 somatolactotropes, Endocrinology, 145, 3075, 10.1210/en.2004-0228 · DOI
  23. Croston, 1997, Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes, Endocrinology, 138, 3779, 10.1210/endo.138.9.5404 · DOI
  24. Zhao, 2006, Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote, Am. J. Hum. Genet., 79, 514, 10.1086/507488 · DOI
  25. Cunningham, 2007, Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia, Nat. Struct. Mol. Biol., 14, 413, 10.1038/nsmb1235 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Mayne, J., Raymond, A., Chaplin, A., Cousins, M., Kaefer, N., Gyamera-Acheampong, C., Seidah, N. G., Mbikay, M., Chrétien, M., & Ooi, T. C.
Venue
Biochemical and Biophysical Research Communications
Publisher
Elsevier BV
Published
2007-09
Volume
361
Issue
2
Pages
451-456
ISSN
0006-291X
DOI
10.1016/j.bbrc.2007.07.029
Cited by
81
References
3
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review